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1. Introduction  
 
This Risk Assessment Report presents the summary findings and the conclusions of the risk 
assessment carried out by the EMCDDA’s extended Scientific Committee of the new 
psychoactive substance 4-methylmethcathinone (hereinafter ‘mephedrone’). The report has 
been prepared and drafted in accordance with the conceptual framework and the procedure set 
out in the Operating guidelines for risk assessment of new psychoactive substances (EMCDDA, 
2010). It is written as a stand-alone document which presents detailed information on and 
analysis of the scientific and law enforcement data available at this time. The conclusion section 
of the report summarises the main issues addressed and reflects all opinions held by the 
members of the Committee. A more detailed ‘Technical report on mephedrone’ is annexed to 
this report (Annex 1). 
 
The risk assessment has been undertaken in compliance with Article 6 of Council Decision 
2005/387/JHA of 10 May 2005 on information exchange, risk assessment and control of new 
psychoactive substances (1) (hereinafter the ‘Decision’). The Decision establishes a mechanism 
for the rapid exchange of information on new psychoactive substances that may pose public-
health and social threats, including the involvement of organised crime, thus allowing European 
Union institutions and Member States to act on all new narcotic and psychotropic substances (2) 
that appear on the European Union drug scene. The Decision also provides for an assessment 
of the risks associated with these new psychoactive substances so that, if applicable, measures 
in the Member States for the control of narcotic and psychotropic substances (3) can be applied 
to these new substances.  
 
There is emerging evidence that the new psychoactive substance mephedrone is being used as 
a recreational drug in Europe. In response to this, in compliance with the provisions of Article 5 
of the Decision, on 25 March 2010, the EMCDDA and Europol submitted to the Council, the 
Commission and the European Medicines Agency (EMA) a Joint Report on the new 
psychoactive substance 4-methylmethcathinone (mephedrone) (4). Taking into account the Joint 
Report's conclusion, and in accordance with Article 6 of the Decision, on 26 May 2010, the 
Council formally requested that ‘the risk assessment should be carried out by the extended 
Scientific Committee of the EMCDDA and be submitted to the Commission and the Council 
within twelve weeks of this notification’.  
 
In accordance with Article 6.2, the meeting to assess the risks of mephedrone was convened 
under the auspices of the EMCDDA’s Scientific Committee with the participation of five 
additional experts designated by the Director of the EMCDDA, acting on the advice of the 
Chairperson of the Scientific Committee, chosen from a panel proposed by Member States and 
approved by the Management Board of the EMCDDA. The additional experts are from scientific 
fields that are not represented, or not sufficiently represented, on the Scientific Committee, and 
whose contribution is necessary for a balanced and adequate assessment of the possible risks 
                                                 
(1) OJ L 127, 20.5.2005, p. 32. 
 
(2)  According to the definition provided by the Council Decision, a ‘new psychoactive substance’ means a new narcotic drug 
or a new psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form or in a 
preparation that has not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, and that 
may pose a threat to public health comparable to the substances listed in Schedule I, II or IV; ‘new psychotropic drug’ 
means a substance in pure form or in a preparation that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat to public health comparable to the substances listed 
in Schedule I, II, III or IV. 
 
(3) In compliance with the provisions of the 1961 UN Single Convention on Narcotic Drugs and the 1971 UN Convention on 
Psychotropic Substances. 
(4) 8145/10 CORDROGUE 36/SAN 68. 
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of mephedrone, including, health and social risks. Furthermore, one expert from the 
Commission, one expert from Europol and two experts from the European Medicines Agency 
(EMA) participated in the risk assessment. The meeting took place on 15 July 2010 at the 
EMCDDA in Lisbon. The risk assessment was carried out on the basis of information provided 
to the Scientific Committee by the Member States, the EMCDDA, Europol and the EMA. A full 
list of the extended Scientific Committee, as well as the list of participants, attending the risk 
assessment meeting, is annexed to this report (Annex 2). 
 
For the risk assessment, the Scientific Committee considered the following: 
 
(i) Technical report on mephedrone (July 2010) — Annex 1 to the Risk Assessment 
Report; Appendix 1 to the Technical report, ‘Mephedrone: assessment of health risks 
and harms’ (July 2010) (EMCDDA-commissioned cross-sectional survey of UK 
clubbers); and Appendix 2 to the Technical report, ‘Mephedrone: additional studies. 
Overview of prevalence, use patterns, effects’ (July 2010).  
(ii) Europol–EMCDDA Joint Report on a new psychoactive substance: 4-
methylmethcathinone (mephedrone) (5); 
(iii) Scientific articles, official reports, media articles and grey literature; 
(iv) Operating guidelines for risk assessment of new psychoactive substances, 
(EMCDDA, 2010) (6); 
(v) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances.  
2. Physical and chemical description of mephedrone and its mechanisms of action, 
including its medical value 
 
Mephedrone is the common name for 4-methylmethcathinone. The systematic IUPAC name is: 
(RS)-2-methylamino-1-(4-methylphenyl)propan-1-one. It is a synthetic ring-substituted cathinone 
closely related to the phenethylamine family, differing only by a keto functional group at the beta 
carbon. The molecular formula for mephedrone is C11H15NO, equating to a molecular weight of 
177.242 g/mol. Chemical Abstracts Service (CAS) registry numbers of mephedrone are 
1189805-46-6 (base) and 1189726-22-4 (hydrochloride salt). In addition to mephedrone, 
positional isomers of methylmethcathinone include 2-methylmethcathinone and 3-
methylmethcathinone.  
 
Mephedrone hydrochloride salt is a white powder, while its free base is a yellowish liquid at 
ambient temperature. Mephedrone is typically sold as crystalline powder — stable, water-
soluble, white or lightly coloured hydrochloride salt; most probably as a racemic mixture of the R 
and S enantiomers. The powder is readily soluble in water and can be dissolved for oral/rectal 
use or for injection. Mephedrone has also been found as capsules containing powder and as 
tablets pressed from powder. 
 
Mephedrone is metabolised by a number of pathways to the following metabolites: nor-
mephedrone, nor-dihydro mephedrone, nor-hydroxytolyl mephedrone, 4-carboxy-dihydro 
mephedrone, hydroxytolyl mephedrone. It is thought that the hydroxytolyl mephedrone and nor-
hydroxytolyl mephedrone metabolites are partly excreted as glucuronide and sulphate 
conjugates. There is no data available to be able to determine how long either mephedrone or 
its metabolites remain detectable, nor on their stability in biological specimens.  
 
Gas chromatography coupled with mass spectrometry (GC-MS) and liquid chromatography 
tandem mass spectrometry (LC-MS/MS) techniques have been developed for the analysis of 




mephedrone and some of its metabolites/precursors. The mass-spectrometry technique does 
not distinguish between methylmethcathinone isomers; however nuclear magnetic resonance 
spectroscopy (NMR) and other techniques allow the isomers to be differentiated. Immunoassay 
field tests for methamphetamine give false positive reactions with some cathinone derivatives. 
 
Mephedrone has no established or acknowledged medical value or use (human or veterinary) in 
the European Union. There is no marketing authorisation (existing, ongoing or suspended) for 
mephedrone in the European Union or in the Member States. There is no information that 
mephedrone is used for the manufacture of a medicinal product or an active pharmaceutical 
ingredient (API) of a medicinal product in the European Union. There remains a theoretical 
possibility that mephedrone could be used for the synthesis of some API of veterinary or human 
medicinal products (e.g. ephedrine, pseudo-ephedrine and pyrovalerone). No data exists to 
suggest that this is currently the case but it should be noted that there is no European Union 
database on the synthetic routes of all registered medicinal products. 
 
Mephedrone is commercially available from suppliers on the Internet where it can be purchased 
in bulk. There are no indications that mephedrone may be used for any other legitimate 
purposes. There are no known uses of mephedrone as a component in industrial, cosmetic or 
agricultural products.  
 
Mephedrone is reported to be used in single doses of between 5–250 mg, although due to 
short-lived effects the total doses used per session may be greater, possibly between 0.5–2 g. 
Onset of desired effects is typically seen within 15–45 minutes of oral ingestion and a few 
minutes after nasal insufflation. Users report that the desired effects last approximately 2–3 
hours and therefore that they may consume multiple doses during a session to prolong the 
duration of the desired effects.  
 
There are no formal pharmacodynamic studies looking specifically at mephedrone. Based on its 
chemical structure, it is likely that it has a similar mechanism of action to other stimulant drugs 
(blocks reuptake of, and stimulates the release of stimulant neurotransmitters such as serotonin, 
dopamine and norepinephrine). This is further supported by the sympathomimetic effects 
(dilated pupils, tachycardia, hypertension, agitation) seen with mephedrone use that are similar 
to other stimulant drugs such as MDMA and cocaine.  
 
There are no published formal studies assessing the psychological and/or behavioural effects of 
mephedrone in humans. In addition, there are no animal studies on which to base an 
extrapolation of potential effects. However, users report that the desired psychological and 
behavioural effects of mephedrone include euphoria, general stimulation, enhanced music 
appreciation, elevated mood, decreased hostility, improved mental function and mild sexual 
stimulation. These effects are broadly comparable to those reported for better-studied stimulant 
drugs.  
3. Chemical precursors that are used for the manufacture of mephedrone 
 
The synthesis of mephedrone, mentioned as ‘toluyl-alpha-monomethyl-aminoethylcetone’, was 
first described in 1929 by Saem de Burnaga Sanchez. The most straightforward route of 
synthesis for mephedrone is by reacting the suitably substituted bromopropiophenone with 
methylamine; the resulting product is always racemic. Therefore, mephedrone is most likely 
synthesised by bromination of 4-methylpropiophenone (1-(4-methylphenyl)-1-propanone) 
followed by reaction of the resulting 4-methylbromopropiophenone (1-(4-methylphenyl)-2-
bromo-1-propanone) with an excess of methylamine or methylamine hydrochloride and an acid 
scavenger. The reaction is then quenched with gaseous or aqueous hydrochloride providing the 
hydrochloride salt that needs to be recrystallised. This is a relatively straightforward option 
because the starting materials are often commercially available or easily synthesised. This 
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requires similar equipment and chemical knowledge to that needed for the synthesis of, for 
example, amphetamine or MDMA. The main precursor of mephedrone, 4-methylpropiophenone, 
is commercially available on the Internet. 
 
There is the potential that if the substituted ephedrine analogue (4-methylephedrine) is 
available, then its oxidation with, for example, potassium permanganate or potassium 
dichromate is also a feasible method that does not require a professional laboratory. There is no 
evidence that this is currently occurring in Europe. This method, similar to the one used for the 
clandestine synthesis of methcathinone, requires reacting the precursor with a solution of 
potassium permanganate in diluted sulphuric acid. The precursor can be obtained in a specific 
enantiomeric form, ensuring that the synthesis is stereoselective. One of the possible hazards of 
the permanganate process could be that users can suffer manganese poisoning if the product is 
not purified.  
 
However, analysis of seized and purchased mephedrone has shown that it is generally of high 
purity (>95 %). There is limited evidence that precursors used in the manufacture of 
mephedrone are found in the final product. 
 
Alternative synthetic methods, though more cumbersome, have been described in the literature 
such as the Hartung-Munch procedure. More synthetic routes for mephedrone may exist. 
 
Reports from at least four Member States indicated legal production and distribution from Asia 
and in particular from China and bordering countries in South-East Asia. Final packaging of 
mephedrone, prior to sale, seems to be carried out by European suppliers. There have also 
been seizures of tableting machines used for mephedrone processing in Europe, indicating that 
the drug has also been prepared for sale on the illicit market.  
4. Health risks associated with mephedrone 
 
Other than clinical data on acute mephedrone toxicity, and limited reports on fatalities, the 
studies available on mephedrone are few, largely preliminary and focused on user self-reports. 
To date no epidemiological data on prevalence has been published. The majority of studies 
originate from the United Kingdom and evidence from other Member States is scarce. The most 
detailed studies have been undertaken through surveys of UK clubbers, although some 
information can be found on mephedrone use and potential risks regarding other sub-
populations.  
 
Individual health risks 
 
The assessment of individual health risks includes consideration of mephedrone’s acute and 
chronic toxicity, its dependence potential, and similarities and differences to other reference 
stimulants. 
 
Systematic data are not routinely collected in Europe on acute toxicity related to mephedrone 
or closely comparable recreational drugs. Therefore, information on these effects of 
mephedrone is limited to user reports and clinical data on individuals presenting with acute 
mephedrone toxicity to specialist hospitals with a focus on recreational drug toxicity. The 
reported short-term effects of mephedrone use have much in common with those of other 
stimulants. Some self-reports from users favourably compare mephedrone’s effects, saying the 
high can be both better and longer lasting than cocaine.  
 
The main routes of administration for mephedrone are reported as snorting (nasal 
insufflation) and swallowing (oral ingestion), sometimes after dissolving with water. As 
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mephedrone is primarily available in powder form, injecting use is reported but appears to be 
rare.  
 
Adverse effects reported by users include sweating, headaches, tachycardia, palpitations, 
nausea, chest pain, bruxism (teeth grinding), agitation/aggression and paranoia. In addition, 
nasal insufflation of mephedrone is reported to be associated with significant nasal irritation and 
pain which has led to some users switching to oral use of mephedrone. Users report increased 
sexual arousal but there is insufficient information to detect whether this is associated with high-
risk sexual behaviour. 
 
Some detailed information on the patterns of acute mephedrone toxicity is available from clinical 
case series from poisons information services and specialist hospitals in the United Kingdom 
and Sweden, including one series of analytically confirmed acute mephedrone toxicity from the 
United Kingdom. In this data, patients typically present with sympathomimetic features (dilated 
pupils, agitation, tachycardia, hypertension); severe clinical features such as chest pain, 
significant hypertension, arrhythmias and seizures have been reported in a small number of 
cases to date. Similar to other stimulant drugs, it is likely that the risk of toxicity is related to the 
dose of mephedrone used; however there is insufficient information available from toxicity 
reports to determine a ‘dose threshold’ and/or whether particular routes of use are more likely to 
be associated with toxicity. It is possible that certain rare, but clinically significant, severe effects 
are associated with mephedrone use. However, as experience of the toxicological profile of the 
drug is currently limited to a few hundred cases it is difficult to be sure.  
 
Data from individuals presenting with acute mephedrone toxicity suggest that the majority of 
individuals have used at least one other substance together with mephedrone. However there 
are analytically confirmed cases of lone mephedrone toxicity. This is similar to individuals 
presenting with acute toxicity related to other stimulant drugs. 
 
There are two reported fatalities in which mephedrone appears to be the sole cause of death 
(one in Sweden and one in the United Kingdom). In addition to these cases, there are at least 
another 37 deaths in the United Kingdom and Ireland in which mephedrone has been detected 
in post-mortem blood and/or urine toxicology screening. In some of these cases it is likely that 
other drugs and/or other medical conditions or trauma may have contributed to or been 
responsible for death. The inquests into the deaths are pending for the majority of these cases 
therefore it is not possible at this time to determine the contribution of mephedrone. 
 
Strong craving for the substance is reported by some users’ self-reports, sometimes rated 
higher than that experienced with other stimulant drugs. This is cited as a main reason for using 
more mephedrone than intended, and for using for longer periods than planned. Withdrawal 
symptoms do not appear to be significant for most users with the primary symptoms of nasal 
congestion and fatigue most probably related to route of use and lack of sleep secondary to 
staying up late. However the other reported findings, in heavier users, would be consistent with 
a stimulant withdrawal syndrome. There is some evidence that the drug has a high abuse 
liability with over 30 % of the UK telephone survey sample reporting three or more DSM criteria 
of dependence and being classified as dependent. Tolerance, loss of control, a strong urge to 
use and using despite problems predominate. In addition, there are reports from the United 
Kingdom of mephedrone dependence being reported to drug treatment services that suggest 
psychological rather than physical dependency similar to other stimulant drugs. 
 
No studies have been published investigating the potential for chronic mephedrone toxicity 
associated with mephedrone use, including reproductive toxicity, genotoxicity and carcinogenic 
potential.  
 
Reports suggest mephedrone may be used as an alternative to illicit stimulants. The reasons 
given for using mephedrone include: value for money, product purity and consistency as well as 
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the poor availability or low quality of other stimulants (cocaine, ecstasy/MDMA). Some users 
noted a preference for mephedrone over other stimulant drugs with data from the UK clubbers 
rating mephedrone above ecstasy and cocaine for strength and pleasurable high. Mephedrone 
users in the UK telephone survey reported on the considerable impact mephedrone had on their 
consumption of cocaine and ecstasy, with approximately two thirds of the sample reporting that 
they now took less MDMA, and a third reporting that they now consumed less cocaine. Just 
under half of the group reported they would choose mephedrone over cocaine and only a 
quarter said that they would take mephedrone over ecstasy. 
 
The physical effects reported by mephedrone users are typical of other stimulants and may be 
particularly similar to MDMA. However, mephedrone’s relatively short duration of action, leading 
to repeat dosing, is more analogous to cocaine.  
 
In summary, from the data sources available, it appears that the effect profile and clinical 
presentations of mephedrone intoxications share some features seen with MDMA and some 
features seen with cocaine. Additionally, there are very limited reports of fatalities directly 
related to mephedrone. Some users have reported negative effects and in some cases these 
have required medical attention. Similar to other stimulant drugs, the extent to which users 
experience problems requires further investigation. Data also suggest that mephedrone has a 
potential to cause dependency. However, more in-depth studies would be required to explore in 
detail the dependence potential of this drug.  
 
Public health risks 
 
The public health risks associated with mephedrone may be categorised in terms of the extent, 
frequency and patterns of use; availability and quality of the drug; information availability and 
levels of knowledge amongst users; and negative health consequences. 
 
Evidence of use of mephedrone and toxicity associated with its use has been increasing, 
particularly in 2009 and 2010. In the absence of representative studies, prevalence rates are 
difficult to estimate. Non-representative studies provide self-reports that place lifetime use of 
mephedrone at around 40 % amongst UK clubbers responding to an Internet survey (33 % last 
month use), 20 % amongst Scottish students and 40 % amongst Northern Irish school children 
attending focus groups. In other countries, levels of use are largely undocumented. Data from 
the French TREND system describe its use as restricted to a small, primarily Parisian milieu. 
Qualitative reports note the use of the drug in other countries but give no indication of 
prevalence even within high-risk subpopulations.  
 
Mephedrone users are reported to be predominantly male and aged between their late teens 
and late twenties, although both younger and older users are identified in UK studies. Some 
surveys suggest individuals use mephedrone alone while other surveys suggest that users 
combine mephedrone with other drugs including alcohol, cannabis and often cocaine, and 
ecstasy. The evidence suggests mephedrone has some appeal for a range of recreational 
stimulant users — with respondents from UK studies also using cocaine/ecstasy/amphetamine, 
and the Dutch respondents also using ecstasy. There is limited data available on where 
mephedrone is used, although it is likely that it is used in the same environments as other 
stimulant drugs, typically clubs/discos, bars/pubs, outdoor music festivals and home 
environments.  
 
Mephedrone consumption has been identified in a range of sub-populations. In addition to 
‘psychonauts’ (7), mephedrone use has been identified in the clubbing and party scene, 
                                                 
(7) There is no agreed definition of the term ‘psychonaut’ but here it is used to broadly describe individuals who seek to 
explore their mind by intentionally inducing altered states of consciousness, in particular, by experimenting with 
psychoactive substances.  
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amongst school and university students (United Kingdom) and gay men (France). There is 
some evidence to suggest rapid spread of mephedrone use, particularly in the United Kingdom 
and in Ireland, but also among clubbers in Slovenia. Use reported in France is described as 
rather localised and limited, whilst in the Netherlands, the available data are confined to a group 
of primary ecstasy users. Although much of the evidence is linked to use amongst clubbers, the 
UK studies also include unemployed users and students from Scotland and Northern Ireland. In 
addition, there are reports of spread of mephedrone use amongst opiate users in Ireland.  
 
In terms of frequency of use, reports suggest recreational, weekend/monthly use is a common 
pattern for those who try, and choose to continue to use, mephedrone. As such mephedrone is 
used in a similar way to ecstasy or cocaine in party and nightlife settings. Around 15 % of UK 
Internet survey respondents reported using mephedrone at least weekly. A small number of 
users appear to progress to daily use. Mephedrone is reported as being used primarily in 
combination with alcohol, cannabis and other stimulants. These combinations of substances 
makes it more difficult to identify mephedrone-specific effects. Relatively high concurrent 
consumption of ketamine was reported by UK clubbers. There are anecdotal reports of opiates 
injecting users switching to mephedrone when opiates are not available. 
 
Some concerns have been raised about young people experimenting with the practice of 
snorting the drug, a route of administration commonly associated to cocaine. However, a 
significant proportion of those using mephedrone by nasal insufflation report nasal irritation and 
pain, leading to a change to the oral route.  
 
Mephedrone is available for purchase on the Internet, from head shops and from established 
street-level dealers. Where information on purchase of mephedrone is available, it appears 
most common to buy the drug from a dealer or from friends. Some users reported buying from 
the Internet, and this tended to be higher quality mephedrone, but for some users the risk of 
Internet data security was a deterrent. Internet suppliers will ship mephedrone to EU countries 
often marketed as ‘plant food’, ‘bath salt’ or ‘research chemical’, presumably to circumvent 
control measures. Very rarely mephedrone is sold explicitly as a ‘legal high’. EMCDDA Internet 
monitoring shows that the number of websites selling mephedrone increased from December 
2009 to March 2010. But subsequent to the April 2010 classification of mephedrone in the 
United Kingdom, there was a rapid and considerable decrease in the number of sites found to 
be operating. Prior to UK control, many suppliers appeared to be based in the United Kingdom, 
or targeting the UK market.  
 
Most sites do not have restrictions on the countries that they will ship mephedrone to, but advise 
buyers to check the legal status in their countries. Internet sites selling mephedrone typically 
differ from those selling other ‘legal highs’ as they are mephedrone/cathinone specific. There is 
generally information available on the supposed purity of the product supplied but rarely 
information on the potential for unwanted effects associated with its use, although most sites 
state that it is not for human consumption. Many sites supply mephedrone in bulk (kilogram) 
quantities in addition to single user doses. However, they typically provide minimal information 
on the dose of mephedrone. Any information that is provided is very general and often cryptic in 
nature; for example mephedrone sold as ‘plant food’ may contain advice on ‘number of doses 
for an average-sized plant’. It is likely that users will interpret this information as the number of 
doses to be taken by an adult. The UK control seems to have prompted the appearance of at 
least two new substances and products marketed on the Internet as ‘legal highs’. There is also 
some evidence to suggest that where mephedrone has been controlled, the drug continues to 
be available on the illicit market. 
 
In general, the quality and purity of mephedrone available to users is reported as high, and the 
analysis of seized and purchased mephedrone confirms this. However, some samples of 
mephedrone have been found to contain pharmaceutical agents (e.g. benzocaine, lidocaine, 
caffeine and paracetamol), other synthetic cathinones (e.g. butylone, methylone, ethylcathinone, 
 10 
fluoromethcathinone, methylenedioxypyrovalerone/MDPV) and/or other recreational drugs (e.g. 
MDMA, mCPP, ketamine).  
 
There is anecdotal evidence that extensive media coverage of mephedrone has led to 
increased general population and user awareness of the drug and, in particular, to the fact that it 
is legally available over the Internet for delivery to Europe. Some users have stated that they 
first bought and used mephedrone after reading reports about it in the popular press. The media 
is also cited as a primary source of (often inaccurate) information about the drug. Typically, 
there appears to be a low level of knowledge amongst some groups of users of the chemical 
content of products and chemical make-up of mephedrone. However, the Internet has also been 
a source of information for those interested in drugs. Specialist websites/user forums indicate 
that users are aware that mephedrone is effective in producing the desired effects and may 
compare favourably to other stimulants.  
 
Misunderstanding and misinformation about mephedrone may also be an important issue 
both with respect to the use and to the supply of the drug. It should be noted that there are a 
number of other synthetic cathinones that are used recreationally — these include methedrone, 
methylone and MDPV. Some of these, along with other non-cathinone drugs such as 
methadone, have similar sounding names to mephedrone which may cause confusion amongst 
users, healthcare professionals, law enforcement agencies and the media. As cathinone 
derivatives are also sold under generic brand names, with no labelling of the active constituent 
chemicals, both users and sellers may be unaware of what particular substance is being 
consumed. This problem may be amplified by the fact that products can contain mixtures of 
cathinones and other drugs. It is likely that this is more of an issue with products purchased 
mostly from street dealers rather than from the Internet. Feedback from pill/powder-testing 
(Netherlands, France) report that some users were unaware that the substance they had 
purchased was mephedrone before test results were provided. This suggests that mephedrone 
has also been used unknowingly by those buying ecstasy tablets on the illicit market. Finally, 
the marketing of mephedrone may itself cause further confusion, as illustrated by a report of 
school pupils being uncertain as to whether all regular plant food also contained the drug.  
 
Mephedrone has been detected on post-mortem analysis in four road traffic accident related 
deaths in the United Kingdom; however inquests into these deaths are awaited and so it is not 
possible to determine the role that mephedrone played. There is no data available from other 
European countries or from law enforcement agencies to suggest that mephedrone use has 
been implicated in road traffic accidents or other trauma. This may, at least in part, be due to the 
fact that, at this time, mephedrone is not widely tested for by forensic laboratories. 
5. Social risks associated with mephedrone 
 
The information pertaining to social risks associated with mephedrone is very limited. Whilst 
there is some limited evidence to suggest greater use of mephedrone compared to other 
stimulant drugs amongst students of school and college/university age, there have been no 
studies to determine the impact of mephedrone use on educational outcomes such as 
attendance, concentration and exam performance. Similarly, there is no data on the effect of 
mephedrone use on performance/attendance at work, career progression, effects on personal 
relationships or neglect of family.  
 
There are some healthcare costs associated with cases of acute mephedrone toxicity 
presenting to hospitals. Most of these involve short assessments within the emergency 
department; however there are a minority that require critical care admission with greater 
associated costs. There is also evidence that users are switching from other controlled stimulant 
drugs to mephedrone. However, it is not possible at this time to estimate whether mephedrone 
is associated with greater healthcare costs than other stimulant drugs.  
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There is no evidence related to levels of acquisitive crime resulting from mephedrone use. 
There have been media and anecdotal reports of some crime and violence reportedly related to 
mephedrone; however the veracity of these reports is unclear.  
 
There are both media and anecdotal reports of links between mephedrone and violence in 
Northern Ireland where sellers of the drug appear to have become caught up with the 
paramilitary activism and informal social control of the drug market. Reports suggest 
punishment beatings/shootings have been on the increase recently regarding the sale and use 
of mephedrone. A study with school children reported that mephedrone was more easily 
accessible than cannabis. 
6. Information on the level of involvement of organised crime and information on 
seizures and/or detections by the authorities, and the manufacture of mephedrone 
 
Since March 2008, mephedrone seizures have been reported in 22 Member States and two 
other countries that report to the EMCDDA. The largest single seizure of mephedrone in Europe 
occurred in the Netherlands in October 2009 when more than 130 kilograms of mephedrone 
(equalling approximately 260 000 tablets) were seized from a tableting site and four related 
storage locations. However, most of the Member States reported small- to medium-sized 
seizures. Two countries — Sweden and the United Kingdom — reported analyses for seizures 
by year and/or by semester. Sweden provided a breakdown for 2008 (82 seizures amounting to 
approximately 4.7 kg) and for 2009 (346 seizures totalling 8.7 kg). The United Kingdom reported 
an increasing trend in seizures: from 2 in 2008 to 20 in the first half of 2009 to 600 in the second 
half of 2009. Over 97 % of the seizures in the United Kingdom occurred in powder form and 
amounted to more than 37 kg.  
 
In addition to seizures, mephedrone was detected either through formal drug analysis schemes 
or ad-hoc test purchases in at least six Member States. In one Member State, initial growth in 
detections of mephedrone in ecstasy tablets appears to have been followed by a decline. The 
reported mephedrone detections refer to various physical forms, mostly powder but also tablets, 
capsules and liquids. In general, it is not uncommon to find mephedrone in combination with 
other synthetic cathinones. Furthermore, other substances were also encountered in 
combination with mephedrone e.g. MDMA, mCPP and caffeine.  
 
Several Member States reported seizures of mephedrone in tablet form with logo imprints 
indicating that they are sold in the user environment as ecstasy. As mephedrone is available in 
powder form on the Internet, processing activities by organised crime seem to be limited to 
tableting. Altogether, three tableting units were reported from the Netherlands but no other 
Member State reported processing activities. In one of these cases, other psychoactive 
substances such as MDMA and mCPP were also found on the tableting site.  
 
There is no information on money-laundering activities in connection with the production, 
wholesale and/or distribution of mephedrone. Furthermore, there is no data suggesting the 
involvement of the same groups of people in different types of crime. 
 
Indications of international trafficking were reported by two Member States — Germany and 
the Netherlands. There is currently limited information to underpin large-scale processing and 
distribution of mephedrone and the role of organised crime. However, with one Member State 
reporting the involvement of organised crime in trafficking and another confirming organised 
crime involvement in large-scale tableting sites, there may be possible involvement of organised 
crime in the trafficking and wholesale distribution of mephedrone. There is no information on 
incidences of violence in connection with the production, wholesale and/or distribution of 
mephedrone. 
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7. Information on any assessment of mephedrone in the United Nations system 
 
The World Health Organization (WHO) is the specialised UN agency designated for the 
evaluation of medical, scientific and public-health aspects of psychoactive substances under the 
1961 and 1971 UN Conventions. The WHO informed the EMCDDA that 4-methylmethcathinone 
(mephedrone) is currently not under assessment and has not been under assessment by the 
UN system. 
8. Description of the control measures that are applicable to mephedrone in the Member 
States 
 
Mephedrone is not listed for control in the UN Drugs Conventions of 1961 or 1971. In 16 
Member States, mephedrone is not controlled under the terms of the 1961 or 1971 UN 
Conventions.  
 
Eleven Member States — Belgium, Denmark, Germany, Estonia, Ireland, France, Italy, 
Lithuania, Romania, Sweden and the United Kingdom (8) — as well as Croatia and Norway 
control mephedrone under drug control legislation.  
 
In Belgium, the Royal Decree of 13 June 2010 includes the substance in Art 2, §2 of the Royal 
Decree of 22 January 1998, which contains the Belgian list of controlled psychotropics. In 
Denmark, effective from 21 December 2008, the Ministry of Health and Prevention added 
mephedrone and other synthetic cathinone derivatives (e.g. ethylcathinone and flephedrone) to 
list B of controlled substances — mephedrone may only be used for medical or scientific 
purposes. In Germany, as of 22 January 2010, mephedrone is controlled by the 24th Amending 
Regulation on Narcotic Drugs. Within this regulation mephedrone falls under schedule I of the 
Narcotics Act (BtMG) (‘narcotics not eligible for trade and medical prescription’). In Estonia, 
mephedrone is controlled as of 27 November 2009 by Regulation N. 87 of the Ministry of Social 
Affairs, which added the substance to the first list of narcotic and psychotropic substances.  
 
In Ireland, since 11 May 2010, mephedrone and related cathinones are designated by name as 
controlled under the Misuse of Drugs Act, by SI No199 of 2010. In France, mephedrone and its 
salts are classed as narcotics by the decree of 7 June 2010 of the Ministry of Health and Sports, 
effective 11 June 2010. In Italy, on 16 June 2010 a Ministry of Health Decree added 
mephedrone to Table I of the drug control law. In Lithuania, mephedrone was included in the 
first list in the list of ‘Narcotic drugs and psychotropic substances prohibited for medical use’ on 
20 June 2010 by the order of the Minister of Health No. V-540. In Romania, as of 10 February 
2010, mephedrone has been added by Government decision to Table 1 of law 13/2000 in the 
category of ‘drugs of highest risk’. In Sweden, mephedrone has been controlled as a narcotic 
drug since 25 May 2009. In the United Kingdom, mephedrone and other cathinone derivatives 
(using a generic definition) have been added to the list of controlled drugs in Class B by the SI 
no. 1207 of 2010 as of 16 April 2010. In Croatia, mephedrone is controlled under drug control 
legislation as a psychotropic since 4 January 2010 (OG 02/10). In Norway, mephedrone was 
earlier controlled by virtue of an ‘analogue’ approach, considered as a ‘derivative’ of a listed 
substance. Nevertheless, it was specifically added to the Norwegian National Drug List with 
effect from 24 March 2010.  
 
Two Member States — the Netherlands and Finland — apply control measures to 
mephedrone under their medicines legislation. In the Netherlands, mephedrone is classified as 
a medicine and is therefore controlled under medicinal products legislation. In Finland, 
mephedrone is classified as a medicine since September 2008 under the Medicines act 
(395/87). 
                                                 
(8) In European Union protocol order.  
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9. Options for control and the possible consequences of the control measures 
   
Under Article 9.1 of Council Decision 2005/387/JHA, the option for control that is available at 
European Union level is for the Member States to submit the new psychoactive substance 
mephedrone to control measures and criminal penalties, as provided for under their legislation, 
by virtue of their obligations under the 1971 United Nations Convention on Psychotropic 
Substances. 
 
There are no specific European studies on possible consequences of such control measures, 
though the Committee has noted reports from individual countries that have already put 
mephedrone under national control. If this option of control is pursued, the Committee considers 
that the following consequences are possible. It should be noted that all of these possible 
consequences apply to any new psychoactive substance and they are not specific only to 
mephedrone.  
• This control could facilitate the detection and monitoring of trafficking and illegal 
manufacture of mephedrone. In so doing, it could facilitate subsequent international 
law enforcement and judicial cooperation. On the other hand, control measures could 
create an illegal market in mephedrone with the increased risk of associated criminal 
activity, including organised crime.  
• This control could be expected to limit the availability of mephedrone and further 
expansion of a legal market in this drug by restricting its commercial availability from 
both Internet and specialised shops.  
• The risk exists that post-control there may be covert sales of mephedrone on the 
Internet, or continuing sales through newly branded products.  
• This control could impact on both the quality/purity and price of any mephedrone 
supply still available on the illicit market. The extent to which this will impact on public 
health, criminality or levels of use is difficult to predict.  
• A health consequence that can be foreseen as a result of control measures are 
benefits brought about by the presumed reduction in use.  
• However, if a significant number of young users continue to use the drug, costs may 
be incurred by bringing them into contact with the criminal justice system. 
• New control measures would imply additional costs related to law enforcement, 
criminal justice, forensic analysis, testing, etc. 
• This control could lead to replacement with other (established or new) psychoactive 
substances which may in themselves have public health consequences.  
• It is not possible to predict whether there will be health or social consequences from 
any substance that might come to be used as an alternative. 
• At present, there is no reason to expect that this control would impact on current or 
future research by the pharmaceutical or chemical industries. However, the possibility 
that this drug may become of interest in the future, although unlikely, cannot be ruled 
out.  
Similar to the impact of control of other psychoactive substances such as BZP (1-
benzylpiperazine), the Committee further notes from the countries that have already introduced 
a ban on mephedrone that:  
• Other non-controlled drugs have been reported to be marketed as replacement 
substances for mephedrone. However, it is not clear if these substances would have 
appeared independently of any action taken on mephedrone. 
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• There is some evidence to suggest that a ban in some Member States has not 
resulted in the disappearance of mephedrone from the illicit market. It will be 
important to monitor whether the mephedrone availability at street level is from 
stockpiles or has been imported or produced post-ban.  
 
Aside from the option for control under legal parameters of Article 9.1 of the Council Decision, 
there are various other options for control open to Member States individually. They may 
choose to control distribution of it under consumer protection or food safety legislation; to control 
it under medicinal products legislation; and/or to control the importation of the substance.  
 
The EU Regulation 178/2002, and Directives 2001/95/EC and 2001/83/EC, standardise the 
national definitions of food, safe products intended for consumers, and medicinal products for 
human use, respectively. Therefore, it may well be that control options under such laws could 
be applied by all European Union Member States. However, few Member States have reported 
utilising such control measures, and the details of national enforcement mechanisms and 
possible penalties for breach are not known (9). 
 
It is possible to consider restrictions that would limit mephedrone use by introducing specific 
measures related to age limits, or interventions in the production chain. However this option has 
not been pursued by any Member State. 
 
It should be noted that the three positional isomers of methylmethcathinone are not easily 
distinguishable by commonly available analytical techniques. Consequently control of only 4-
methylmethcathinone (mephedrone) could be difficult to enforce. 
10. Conclusion 
 
Mephedrone (4-methylmethcathinone) is a synthetic cathinone found mostly as a powder but 
also as tablets. It has no established or acknowledged medical value or use (human or 
veterinary) in the European Union. There are no indications that mephedrone may be used for 
any other purposes. It is commercially available from suppliers on the Internet where it can be 
purchased in bulk. The main precursor of mephedrone, 4-methylpropiophenone, is also 
commercially available.  
 
The physical effects reported by mephedrone users are typical of other stimulants and may be 
particularly similar to MDMA. There are no published formal studies assessing the psychological 
and/or behavioural effects of mephedrone in humans and in animals. Furthermore, in the 
absence of representative studies, prevalence rates are difficult to estimate. The available 
studies are limited in number, largely preliminary and geographically restricted, and reliant on 
user accounts. Taken as a whole, the scientific evidence base available for drawing conclusions 
is limited and this proviso should be borne in mind when interpreting the findings of the risk 
assessment exercise.  
 
Many of the questions posed by the lack of evidence on the health and social risks of 
mephedrone, as for any new psychoactive substance, could be answered through timely 
research. Further studies are needed, especially with respect to potential toxicity, potential to 
produce dependence and the social consequences related to mephedrone use. 
 
                                                 
(9) One illustrative example of using import legislation is provided by the United Kingdom. Before entry into force of control 
under drugs legislation in the United Kingdom, the Home Secretary wrote to local authorities urging them to use powers 
under the Consumer Protection from Unfair Trading Regulations 2008 and consider enforcement steps to be taken to 
ensure mephedrone is not advertised as a fertiliser or bath salts, following ACMD confirmation that mephedrone has no 
such use. They could also use medicines legislation to seize samples labelled for 'human consumption'. Following advice 
from the ACMD on harms, mephedrone and related compounds were banned from import by removing these substances 
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There is sufficient evidence that mephedrone can be an attractive drug for those seeking 
stimulant psychoactive effects for recreational purposes. In the short time that it has been 
available, mephedrone has established itself in some countries as a sought-after substance in 
its own right, for which some users express preference over other established stimulant drugs. 
Overall, the psychoactive properties of this drug would suggest it has a potential for diffusion to 
other populations and countries, which may constitute a health and social threat. Future 
diffusion is likely to be influenced by many factors including the availability and quality of other 
stimulant drugs.  
 
It appears that the effect profile and clinical presentations of mephedrone intoxications share 
some features seen with MDMA and some features seen with cocaine. The current evidence 
base does not allow an accurate assessment to be made of the extent to which mephedrone 
users are likely to experience health problems. However, sufficient data are available to allow 
the Committee to conclude that some users of the drug do experience acute health problems. In 
general, these are similar to the acute problems reported with use of illicit stimulants. Moreover, 
both user reports and the psychoactive properties of mephedrone would suggest that the drug is 
able to produce dependence in users. Current data are not sufficient to determine the relative 
dependence-producing potential of mephedrone. However, a number of factors would suggest 
that this is a concern that merits further investigation. There have been a very limited number of 
deaths reported to be related directly to the use of mephedrone.  
 
The chronic health effects related to the consumption of mephedrone remain virtually unknown. 
No studies have been published investigating the potential for chronic mephedrone toxicity 
associated with mephedrone use, including reproductive toxicity, genotoxicity and carcinogenic 
potential.  
 
The social consequences associated with the use of any drug are likely to be influenced by a 
number of factors. To date, different patterns of use have been observed. Mephedrone has 
established itself very quickly within the recreational drug market within at least two Member 
States. However, in another Member State initial growth in use/availability appears to have been 
followed by a decline. Limited use of mephedrone among problem drug users has also been 
reported, including mephedrone being injected. Based on the available evidence, it is difficult to 
draw any firm conclusions on the likely social risks associated with mephedrone, but given the 
speed at which the drug has become established and its potential attractiveness to different 
groups of drug users, there is a need for ongoing vigilance.  
 
This drug has been marketed over the Internet and through specialist suppliers; it is also being 
sold by established street dealers. Organised crime has noted the potential for legally 
purchased stimulants to be sold in the illicit drugs market, but international trafficking and the 
involvement of organised crime with mephedrone is relatively limited at present.  
 
The Committee notes that a decision to control this drug has the potential to bring with it both 
positive and negative consequences. Potential positive consequences may include reduced 
availability and use of the drug. It is important, however, to anticipate and minimise any potential 
negative consequences of control. Control measures could create an illegal market in 
mephedrone with the associated risk of criminal activity. Furthermore, control should not inhibit 
the gathering and dissemination of accurate information on mephedrone to users and to 
relevant professionals.  
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